DaVita price target lowered to $104 from $115 at Truist

Truist lowered the firm’s price target on DaVita to $104 from $115 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services that previews the Q3 earnings for the sector. The firm continues to like attractive overarching secular tailwinds, and sees solid fundamentals across much of the group, the analyst tells investors in a research note. Truist adds that it sees continued strong free cash flow generation across the bulk of the sector to drive brisk ongoing growth investment and continued M&A, also noting that risk/reward on the group is favorable.